---
title: "Novoprotein reported a net loss of 54.8068 million yuan for the fiscal year 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229937831.md"
description: "According to the Zhitong Finance APP, Novoprotein released its 2024 annual performance preliminary report, stating that the total operating revenue for 2024 was 127 million yuan, a year-on-year decrease of 16.81%; the net loss attributable to the parent company's owners was 54.8068 million yuan; the net loss attributable to the parent company's owners after deducting non-recurring gains and losses was 72.2141 million yuan; the basic loss per share was 0.78 yuan"
datetime: "2025-02-27T14:59:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229937831.md)
  - [en](https://longbridge.com/en/news/229937831.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229937831.md)
generator: "portal-rs"
---

# Novoprotein reported a net loss of 54.8068 million yuan for the fiscal year 2024

According to the Zhitong Finance APP, Novoprotein (688137.SH) released its annual performance preliminary report for 2024. The total operating revenue for 2024 is 127 million yuan, a year-on-year decrease of 16.81%; the net loss attributable to the parent company's owners is 54.8068 million yuan; the net loss attributable to the parent company's owners after deducting non-recurring gains and losses is 72.2141 million yuan; the basic loss per share is 0.78 yuan

### Related Stocks

- [688137.CN](https://longbridge.com/en/quote/688137.CN.md)

## Related News & Research

- [Gold Rallies to 3-Month High](https://longbridge.com/en/news/296629959.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [IMMU: Vididencel delivers durable remissions in AML and CML, with broad late-stage clinical expansion](https://longbridge.com/en/news/296462827.md)
- [Silver Pony Announces OTC Symbol Change to PONIF Following Name Change | CCCFD Stock News](https://longbridge.com/en/news/296454882.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**